Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses - PubMed (original) (raw)
. 2018 Oct;34(3):489-510.
doi: 10.1007/s12640-018-9906-2. Epub 2018 May 7.
Affiliations
- PMID: 29736827
- DOI: 10.1007/s12640-018-9906-2
Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses
Michael Maes et al. Neurotox Res. 2018 Oct.
Abstract
Accumulating evidence shows that nitro-oxidative pathways play an important role in the pathophysiology of major depressive disorder (MDD) and bipolar disorder (BD) and maybe anxiety disorders. The current study aims to examine superoxide dismutase (SOD1), catalase, lipid hydroperoxides (LOOH), nitric oxide metabolites (NOx), advanced oxidation protein products (AOPP), malondialdehyde (MDA), glutathione (GSH), paraoxonase 1 (PON1), high-density lipoprotein cholesterol (HDL), and uric acid (UA) in participants with and without generalized anxiety disorder (GAD) co-occurring or not with BD, MDD, or tobacco use disorder. Z unit-weighted composite scores were computed as indices of nitro-oxidative stress driving lipid and protein oxidation. SOD1, LOOH, NOx, and uric acid were significantly higher and HDL and PON1 significantly lower in participants with GAD than in those without GAD. GAD was more adequately predicted by increased SOD + LOOH + NOx and lowered HDL + PON1 composite scores. Composite scores of nitro-oxidative stress coupled with aldehyde and AOPP production were significantly increased in participants with comorbid GAD + MDD as compared with all other study groups, namely MDD, GAD + BD, BD, GAD, and healthy controls. In conclusion, GAD is characterized by increased nitro-oxidative stress and lipid peroxidation and lowered lipid-associated antioxidant defenses, while increased uric acid levels in GAD may protect against aldehyde production and protein oxidation. This study suggests that increased nitro-oxidative stress and especially increased SOD1 activity, NO production, and lipid peroxidation as well as lowered HDL-cholesterol and PON1 activity could be novel drug targets for GAD especially when comorbid with MDD.
Keywords: Bipolar disorder; Generalized anxiety disorder; Immune; Inflammation; Major depressive disorder; Oxidative and nitrosative stress.
Similar articles
- In major affective disorders, early life trauma predict increased nitro-oxidative stress, lipid peroxidation and protein oxidation and recurrence of major affective disorders, suicidal behaviors and a lowered quality of life.
Moraes JB, Maes M, Roomruangwong C, Bonifacio KL, Barbosa DS, Vargas HO, Anderson G, Kubera M, Carvalho AF, Nunes SOV. Moraes JB, et al. Metab Brain Dis. 2018 Aug;33(4):1081-1096. doi: 10.1007/s11011-018-0209-3. Epub 2018 Mar 14. Metab Brain Dis. 2018. PMID: 29542039 - Major Differences in Neurooxidative and Neuronitrosative Stress Pathways Between Major Depressive Disorder and Types I and II Bipolar Disorder.
Maes M, Landucci Bonifacio K, Morelli NR, Vargas HO, Barbosa DS, Carvalho AF, Nunes SOV. Maes M, et al. Mol Neurobiol. 2019 Jan;56(1):141-156. doi: 10.1007/s12035-018-1051-7. Epub 2018 Apr 21. Mol Neurobiol. 2019. PMID: 29681025 - Common Environmental Factors May Underpin the Comorbidity Between Generalized Anxiety Disorder and Mood Disorders Via Activated Nitro-oxidative Pathways.
Roomruangwong C, Simeonova DS, Stoyanov DS, Anderson G, Carvalho A, Maes M. Roomruangwong C, et al. Curr Top Med Chem. 2018;18(19):1621-1640. doi: 10.2174/1568026618666181115101625. Curr Top Med Chem. 2018. PMID: 30430941 Review. - Increased nitro-oxidative toxicity in association with metabolic syndrome, atherogenicity and insulin resistance in patients with affective disorders.
Morelli NR, Maes M, Bonifacio KL, Vargas HO, Nunes SOV, Barbosa DS. Morelli NR, et al. J Affect Disord. 2021 Nov 1;294:410-419. doi: 10.1016/j.jad.2021.07.057. Epub 2021 Jul 18. J Affect Disord. 2021. PMID: 34320448 - Reverse cholesterol transport and lipid peroxidation biomarkers in major depression and bipolar disorder: A systematic review and meta-analysis.
Almulla AF, Thipakorn Y, Algon AAA, Tunvirachaisakul C, Al-Hakeim HK, Maes M. Almulla AF, et al. Brain Behav Immun. 2023 Oct;113:374-388. doi: 10.1016/j.bbi.2023.08.007. Epub 2023 Aug 7. Brain Behav Immun. 2023. PMID: 37557967 Review.
Cited by
- Do SOD2 and SOD3 gene polymorphisms impact the oral health-related quality of life in Para athletes?
Silveira ACJ, Guimarães LS, VON Held R, Silva EBD, Silveira FM, Oliveira Neto ZC, Scariot R, Winckler C, Küchler EC, Brancher JA, Antunes LAA, Antunes LS. Silveira ACJ, et al. Braz Oral Res. 2024 Aug 5;38:e074. doi: 10.1590/1807-3107bor-2024.vol38.0074. eCollection 2024. Braz Oral Res. 2024. PMID: 39109770 Free PMC article. - Are Advanced Oxidation Protein Products (AOPPs) Levels Altered in Neuropsychiatric Disorders? An Integrative Review.
de Brum GF, Bochi GV. de Brum GF, et al. Mol Neurobiol. 2024 Apr 6. doi: 10.1007/s12035-024-04122-7. Online ahead of print. Mol Neurobiol. 2024. PMID: 38580854 Review. - Biological Markers in Newly Diagnosed Generalized Anxiety Disorder Patients: 8-OHdG, S100B and Oxidative Stress.
Oktay M, Asoğlu M, Taskin S, Kirmit A. Oktay M, et al. Neuropsychiatr Dis Treat. 2024 Jan 6;20:19-24. doi: 10.2147/NDT.S444506. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 38204917 Free PMC article. - Prognostic Factors Associated With Sleep Duration: Serum Pro-Oxidant/Antioxidant Balance and Superoxide Dismutase 1 as Oxidative Stress Markers and Anxiety/Depression.
Darroudi S, Eslamiyeh M, Jaber Al-Fayyadh KK, Zamiri Bidary M, Danesteh S, Hassanzadeh Gouji A, Darban RA, Esmaily H, Ghayour-Mobarhan M, Moohebati M, Ferns GA. Darroudi S, et al. Int J Public Health. 2023 Sep 7;68:1606014. doi: 10.3389/ijph.2023.1606014. eCollection 2023. Int J Public Health. 2023. PMID: 37744415 Free PMC article. - Serum Levels of 8-Iso-Prostaglandin F2α and Raftlin in Patients with Generalized Anxiety Disorder.
Hursitoğlu O, Kurutas EB. Hursitoğlu O, et al. Clin Psychopharmacol Neurosci. 2023 May 30;21(2):370-376. doi: 10.9758/cpn.2023.21.2.370. Clin Psychopharmacol Neurosci. 2023. PMID: 37119229 Free PMC article.
References
- Depress Anxiety. 2008;25(4):300-16 - PubMed
- Toxicol Appl Pharmacol. 2009 Feb 15;235(1):1-9 - PubMed
- Comp Biochem Physiol C Toxicol Pharmacol. 2005 Jan;140(1):47-52 - PubMed
- Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):676-92 - PubMed
- Psychiatry Clin Neurosci. 2018 Feb;72(2):116-130 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous